MedPath

Effects of the oral monophasic contraceptive pill CG 5025 (Belara/0,03 mg etinyl estradiol and 2 mg chlormadinonacetate) on the cosmetic hairquality in women wishing to use hormonal contraceptio

Conditions
unaesthetic hairquality in woman wishing to use hormonal contraception
Registration Number
EUCTR2007-007489-39-DE
Lead Sponsor
niversity of Hamburg, MIN-Faculty, Department of Chemistry, Division of Cosmetetic Science
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised-recruitment may be ongoing or finished
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria

•age >18 and <45;
•woman wishing to use hormonal contraception;
•dissatisfaction with the own hairquality;
•written informed consent;
•gynaecological confirmation that participation is medically unobjectionable (not older
than 4 weeks)

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

•pregnancy, lactation;
•alkoholism, drug addiction;
•participation on other clinical trials at the same time or within the last 30 days;
•taking hormonal contraception within the last 4 weeks or especially antiandrogenetic
contraception within the last 3 month
•no written informed consent;
•no gynaecological confirmation that participation is medically unobjectionable

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath